Brief: FDA lifts partial clinical hold on the Takeaim Lymphoma study of emavusertib
18/08/2022 13:07
Aug 18 (Reuters) - Curis Inc CRIS.O :
* FDA LIFTS PARTIAL CLINICAL HOLD ON THE TAKEAIM LYMPHOMA
STUDY OF
EMAVUSERTIB
* CURIS INC - PRELIMINARY CLINICAL DATA UPDATE IN LYMPHOMA
STUDY
EXPECTED IN 2023
Source text for Eikon: ID:nPn4Dk7T0a
Further company coverage: CRIS.O
Recent news on Curis
See all newsCuris Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Curis Announces Pricing Of $5.6 Million Public Offering
Curis Inc expected to post a loss of $7.84 a share - Earnings Preview
Curis Inc expected to post a loss of $7.47 a share - Earnings Preview
Brief: Curis Doses First Five Patients In Takeaim Cll Study